Home » Newsletters » BioWorld Science

BioWorld Science

July 1, 2004

View Archived Issues

Galenica acquisition finalized

Final phase of Estrasorb commercial launch

Vernalis and Biogen Idec collaborate on adenosine A2A receptor antagonists

Isis earns milestone for Macugen NDA filing

Palifermin NDA submitted for oral mucositis

Celecoxib and a poxvirus-based vaccine improve survival in mice with multiple intestinal neoplasia

First clinical trial of HER-2/neu-based vaccine in patients with breast and ovarian cancer

Preliminary data on Exherin in patients with solid tumors

Six related series of opioid analgesics presented by Gruenenthal

BMS researchers describe three series of anti-HIV agents

Lilly claims novel 5-HT/norepinephrine reuptake inhibitors for pain and other uses

Two series of immunomodulating agents newly described by BMS scientists

French researchers identify new protein kinase modulators for diabetes, cancer, etc.

Servier presents new AMPK activators with potential in diabetes and other disorders

Manhattan Pharmaceuticals investigates oleoyl estrone for weight control

Sanofi-Synthelabo and Pfizer conclude agreement on divestment of Campto

Incara changes company name to Aeolus Pharmaceuticals

Advanced Magnetics submits response to Combidex approvable letter

FDA extends action date for Cymbalta

Nabi files for European approval of Nabi-HB Intravenous

U. of Pittsburgh to test AAB-001 for Alzheimer's

Preliminary phase II results for DB-289 in Pneumocystis carinii pneumonia

Approvable letter for oxypurinol for allopurinol-intolerant hyperuricemia

Alimta receives positive opinion in Europe

Phase III PREVENT IV edifoligide study recommended to continue

Immunization completed in phase I ragweed allergy immunotherapy study

NDA submission for new 500 mg formulation of Invirase

New rapid disintegration Aricept formulation launched in Japan

Japanese launch for Serevent 50 Diskus

Mitemcinal reported safe and effective for treating gastroparesis

Preclinical evidence for the effects of rimonabant on body weight and food intake

The efficacy of vardenafil in ED is not affected by glycemic control or diabetes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...